Noradrenergic function and clinical outcome in antidepressant pharmacotherapy

Neuropsychopharmacology

Volumn 24, Issue 6, 2001, Pages 617-623

  Miller, Helen L ^a   Ekstrom, R David ^a   Mason, George A ^a   Lydiard, R Bruce ^b   Golden, Robert N ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antidepressants; Depression; Melatonin; Norepinephrine; Pineal gland

Indexed keywords

6 HYDROXYMELATONIN O SULFATE; FLUVOXAMINE; IMIPRAMINE; MELATONIN; NORADRENALIN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; HUMAN; NORADRENERGIC SYSTEM; PINEAL BODY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINARY EXCRETION;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS; DEPRESSION; FLUVOXAMINE; HUMANS; IMIPRAMINE; MELATONIN; NOREPINEPHRINE; PINEAL GLAND; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0035014137     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00232-3     Document Type: Article

References (38)

1. Arendt J., Bojkowski C., Franey C., Wright J., Marks Y. Immunoassay of 6-hydroxymelatonin sulfate in human plasma and urine. Abolition of the urinary 24-hour rhythm with atenolol J Clin Endocrinol Metab. 60:1985;1166-1173.
2. Axelrod J. The pineal gland. A neurochemical transducer Science. 184:1974;1341-1348.
3. Banerjee S.P., Kung L.S., Riggi S.J., Chanda S.K. Development of B-adrenergic receptor subsensitivity by antidepressants. Nature. 268:1977;455-456.
4. Bauer M.E., Tejani-Butt S.M. Effects of repeated administration of desipramine or electroconvulsive shock on norepinephrine uptake sites measured by [3H]-nisoxetine autoradiography. Brain Res. 582:1992;208-214.
5. Bearn J., Franey C., Arendt J., Checkley S.A. A study of the effects of desipramine treatment alone and in combination with l-triiodothyronine on 6-sulphatoxymelatonin excretion in depressed patients. Br J Psychiat. 155:1989;341-347.
6. Bojkowski C.J., Arendt J., Shih M.C., Markey S.P. Melatonin secretion in humans assessed by measuring its metabolite. 6-sulfatoxymelatonin Clin Chem. 33:1987;1343-1348.
7. Brown G.M., Singer W., Joffe R. Lack of association between thyroid and pineal responses to antidepressant treatment. Depression. 4:1996;73-76.
8. Charney D.S., Menkes D.B., Heninger G.R. Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression Arch Gen Psychiat. 38:1981;1160-1180.
9. Cowen P.J., Fraser S., Sammons R., Green A.R. Atenolol reduces plasma melatonin concentration in man. Br J Clin Pharmacol. 15:1983;579-581.
10. Den Boer J.A., Westenberg H.G.M. Serotonin function in panic disorder. A double-blind placebo-controlled study with fluvoxamine and ritanserin Psychopharmacology. 102:1990;85-94.
11. Frazer A.L., Brown R., Kocsis J., Caroff S., Amsterdam J., Winokur A., Sweeney J., Stokes P. Patterns of melatonin rhythms in depression. J Neural Transm Suppl. 21:1986;269-290.
12. Golden R.N., Markey S.P., Risby E.D., Cowdry R.W., Potter W.Z. Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. Arch Gen Psychiat. 45:1988;150-154.
13. Golden R.N., Potter W.Z. Neurochemical and neuroendocrine dysregulation in affective disorders. Psychiatr Clin North Am. 9:1986;313-327.
14. Golden R.N., Rudorfer M.V., Sherer M., Linnoila M., Potter W.Z. Bupropion in depression. Biochemical effects and clinical response Arch Gen Psychiat. 45:1988;139-143.
15. Gorman J.M., Sullivan G. Noradrenergic approaches to antidepressant therapy. J Clin Psychiat. 61(Suppl 1):2000;13-16.
16. Jarrett D.B., Miewald J.M., Kupfer D.J. Acute changes in sleep-related hormone secretion of depressed patients following oral imipramine. Biol Psychiat. 24:1988;541-554.
17. Kennedy S.H., Brown G.M. Effect of chronic antidepressant treatment with adinazolam and desipramine on melatonin output. Psychiat Res. 43:1992;177-185.
18. Klein D.C., Sugden D., Weller J.L. Postsynaptic α-adrenergic receptors potentiate the β-adrenergic stimulation of pineal serotonin N-acetyltransferase. Proc Natl Acad Sci USA. 80:1983;599-603.
19. Lewy A. Human melatonin secretion. I. A marker for adrenergic function Post R., Ballenger J. Neurobiology of Mood Disorders. 1984;204-214 Williams & Wilkins, Baltimore.
20. Linnoila M., Karoum F., Rosenthal N., Potter W.Z. Electroconvulsive therapy and lithium carbonate. Their effects on norepinephrine metabolism in patients with primary major depression Arch Gen Psychiat. 40:1983;677-680.
21. Markey S.P., Higa S., Shih M., Danforth D.N., Tamarkin L. The correlation between human plasma melatonin levels and urinary 6-hydroxymelatonin excretion. Clin Chim Acta. 150:1985;221-225.
22. Murphy D.L., Tamarkin L., Sunderland T., Garrick N.A., Cohen R. Human plasma melatonin is elevated during treatment with monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl. Psychiat Res. 17:1986;119-127.
23. Nestler E.J., McMahon A., Sabban E.L., Tallman J.F., Duman R.S. Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus ceruleous. Proc Natl Acad Sci USA. 87:1990;7522-7526.
24. Owens M.J. Molecular and cellular mechanisms of antidepressant drugs. Depress Anxiety. 4:1996;153-159.
25. Palazidou E., Papadopoulos A., Ratcliff H., Dawling S., Checkley S.A. Noradrenaline uptake inhibition increases melatonin secretion, a measure of noradrenergic neurotransmission, in depressed patients. Psychol Med. 22:1992;309-315.
26. Potter W.Z., Scheinin M., Golden R.N., Rudorfer M.V., Cowdry R., Calil H., Ross R., Linnoila M. Selective antidepressants and cerebrospinal fluid. Lack of specificity on norepinephrine and serotonin metabolites Arch Gen Psychiat. 42:1985;1171-1177.
27. Reiter R.J. The mammalian pineal gland. Structure and function Am J Anat. 162:1981;287-313.
28. Rudorfer M.V., Scheinin M., Karoum F., Ross R.J., Potter W.Z., Linnoila M. Reduction of norepinephrine turnover by serotonergic drug in man. Biol Psychiat. 19:1984;179-193.
29. Sack R.L., Lewy A.J. Desmethylimipramine treatment increases melatonin production in humans. Biol Psychiat. 21:1986;406-410.
30. Schildkraut J. Neuropharmacology and the affective disorders. Second part. N Engl J Med. 281:1969;248-255.
31. Sugden D., Namboodiri M.A.A., Klein D.C., Pierce J.E., Grady R. Jr., Melford Ovine pineal α1-adrenoceptors. Characterization and evidence for a functional role in the regulation of serum melatonin Endocrinology. 116:1985;1960-1967.
32. Sugden D., Weller J.L., Klein D.C., Kirk K.L., Creveling R. α-Adrenergic potentiation of β-adrenergic stimulation of rat pineal N-acetyltransferase. Biochem Pharmacol. 33:1984;3947-3950.
33. Sugrue M.F. Chronic antidepressant therapy and associated changes in central monoamine receptor functioning. Pharmacol Ther. 21:1983;1-33.
34. Sulser F., Vetulani J., Mobley P. Mode of action of antidepressant drugs. Biochem Pharmacol. 27:1978;257-261.
35. Thompson C., Mezey G., Corn T.H., Franey C., English J., Arendt J., Checkley S.A. The effect of desipramine upon melatonin and cortisol secretion in depressed and normal subjects. Br J Psychiat. 147:1985;389-393.
36. Tollefson GD, Rosenbaum JF (1998): Selective serotonin reuptake inhibitors. In Schatzberg AF, Nemeroff CB (eds), The American Psychiatric Press Textbook of Psychopharmacology, 2nd ed., Washington, DC, American Psychiatric Press, Inc., pp 219-237.
37. Vetulani J., Sulser F. Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature. 257:1975;495-496.
38. Wirz-Justice A., Arendt J. Plasma melatonin and antidepressant drugs. Lancet. 1:1980;425.